These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 30736150

  • 1. Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus.
    Chilton R.
    Expert Rev Endocrinol Metab; 2013 Jul; 8(4):345-349. PubMed ID: 30736150
    [Abstract] [Full Text] [Related]

  • 2. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
    Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N, CAROLINA Investigators.
    JAMA; 2019 Sep 24; 322(12):1155-1166. PubMed ID: 31536101
    [Abstract] [Full Text] [Related]

  • 3. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    Biessels GJ, Janssen J, van den Berg E, Zinman B, Espeland MA, Mattheus M, Johansen OE, CAROLINA® investigators.
    BMC Neurol; 2018 Jan 15; 18(1):7. PubMed ID: 29334906
    [Abstract] [Full Text] [Related]

  • 4. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Dec 15; 14(12):1145-54. PubMed ID: 22974280
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.
    Kadowaki T, Wang G, Rosenstock J, Yabe D, Peng Y, Kanasaki K, Mu Y, Mattheus M, Keller A, Okamura T, Johansen OE, Marx N.
    Diabetol Int; 2021 Jan 15; 12(1):87-100. PubMed ID: 33479584
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.
    Patorno E, Schneeweiss S, Gopalakrishnan C, Martin D, Franklin JM.
    Diabetes Care; 2019 Dec 15; 42(12):2204-2210. PubMed ID: 31239281
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
    Espeland MA, Pratley RE, Rosenstock J, Kadowaki T, Seino Y, Zinman B, Marx N, McGuire DK, Andersen KR, Mattheus M, Keller A, Weber M, Johansen OE.
    Diabetes Obes Metab; 2021 Feb 15; 23(2):569-580. PubMed ID: 33185002
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 15; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial.
    Chen Y, Ning G, Wang C, Gong Y, Patel S, Zhang C, Izumoto T, Woerle HJ, Wang W.
    J Diabetes Investig; 2015 Nov 15; 6(6):692-8. PubMed ID: 26543544
    [Abstract] [Full Text] [Related]

  • 18. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R.
    Curr Med Res Opin; 2015 May 15; 31(5):901-11. PubMed ID: 25775379
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.